We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
When Novartis paid $16 billion to acquire GlaxoSmithKline’s cancer portfolio back in 2015, it picked up a few drugs that didn’t seem to have quite so clear growth prospects...